AstraZeneca Puts Bicycles To Work In Multitarget Deal

 
• By Sukaina Virji

AstraZeneca has entered a broad early stage collaboration with Bicycle Therapeutics to discover and develop bicyclic peptides (Bicycles). If all aspects of the multitarget deal reach fruition, the deal could be worth up to £1bn for the small biotech company.

Bicycle Therapeutics Ltd., led by ex-Pfizer executive Kevin Lee, will be using its bicyclic product platform to identify 'Bicycles' for an undisclosed number of targets specified by AstraZeneca PLC. The big pharma will be responsible for further development and product commercialization. The targets will cover respiratory, cardiovascular and metabolic diseases.

If all planned programs reach the market, Bicycle is eligible for over $1bn in payments, including an upfront, R&D funding,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip